Allotransplantation, performed using an acellular dermal matrix (ADM), plays a significant role in the cultivation of constituted and damaged organs in clinical. Herein, we fabricated an innovative ADM for allografting derived from decellularized human skin by utilizing the supercritical fluid of carbon dioxide to eliminate immunogenic components. By using histological staining, the ADM product demonstrated the successful removal of cellular constituents without exerting any harmful influence on the extracellular matrix. The results from DNA electrophoresis also supported this phenomenon by showing the complete DNA removal in the product, accompanied by the absence of Major Histocompatibility Complex 1, which suggested the supercritical fluid is an effective method for cellular withdrawal. Moreover, the mechanical property of the ADM products, which showed similarity to that of native skin, displayed great compatibility for using our human-derived ADM as an allograft in clinical treatment. Specifically, the cell viability demonstrated the remarkable biocompatibility of the product to human bio-cellular environment which was noticeably higher than that of other products. Additionally, the significant increase in the level of growth factors such as vascular endothelial growth factor, urokinase-type plasminogen activator receptor, granulocyte-macrophage colony-stimulating factor suggested the ability to stimulate cellular processes, proving the products to be innovative in the field of regeneration when applied to clinical in the future. This study provides a thoroughly extensive analysis of the new ADM products, enabling them to be applied in industrial and clinical treatment.

中文翻译：

---

超临界二氧化碳技术用于再生医学的人体皮肤组织有效脱细胞

使用脱细胞真皮基质 (ADM) 进行的同种异体移植在临床上构成和受损器官的培养中起着重要作用。在此，我们通过利用二氧化碳的超临界流体消除免疫原性成分，制造了一种创新的 ADM，用于源自脱细胞人体皮肤的同种异体移植。通过使用组织学染色，ADM 产品证明可以成功去除细胞成分，而不会对细胞外基质产生任何有害影响。DNA 电泳的结果也支持这一现象，显示产品中的 DNA 完全去除，同时不存在主要组织相容性复合物 1，这表明超临界流体是一种有效的细胞提取方法。此外，ADM产品的机械性能，显示出与天然皮肤的相似性，显示出在临床治疗中使用我们的人源 ADM 作为同种异体移植物的良好相容性。具体而言，细胞活力表明该产品对人体生物细胞环境具有显着的生物相容性，明显高于其他产品。此外，血管内皮生长因子、尿激酶型纤溶酶原激活物受体、粒细胞-巨噬细胞集落刺激因子等生长因子水平的显着增加表明具有刺激细胞过程的能力，证明该产品在该领域具有创新性将来应用于临床时再生。本研究对新的 ADM 产品进行了全面广泛的分析，使它们能够应用于工业和临床治疗。